stockrow
Saturday 7 November 2026
Export ALGS’s income statement to Excel — free account
Aligos Therapeutics, Inc.
ALGS Healthcare Biotechnology
Aligos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 million, down 44.6% from fiscal 2024.
- Revenue
- +287.2%
- EPS
- +31.3%
- Free cash flow
- +105.9%
Quarter to September 2026, against a year earlier
4.09
0.42
−9.31%
Follow ALGS
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Piotroski F-Score |
3 | 2 | 3 | — | — | — | — | — | — |
P/S ratio |
42.14 | 63.27 | 5.82 | 2.89 | 108.53 | — | — | — | — |
Altman Z-Score |
(10.99) | (14.28) | (4.96) | (4.52) | 2.87 | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(24.15) | (33.82) | (7.68) | (6.30) | 0.58 | — | — | — | — |
P/Operating CF |
(4.24) | (13.56) | (3.99) | (2.39) | (12.62) | — | — | — | — |
P/B ratio |
1.72 | 0.00 | 0.98 | 0.39 | 2.56 | — | — | — | — |
Price to Tangible BV |
1.72 | 0.00 | 0.98 | 0.39 | 2.56 | — | — | — | — |
EV/Sales |
6.54 | 48.84 | (2.91) | (6.15) | 64.80 | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.53 | 0.91 | 0.00 | — | — | — | — |
EV/Operating CF |
(0.17) | (2.39) | 0.57 | 1.08 | (2.44) | — | — | — | — |
EV/FCF |
(0.17) | (2.38) | 0.57 | 1.07 | (2.42) | — | — | — | — |
Quick Ratio |
3.67 | 2.62 | 5.68 | 3.80 | 4.90 | 8.06 | 8.55 | 12.20 | — |
Current Ratio |
3.90 | 2.86 | 5.90 | 4.03 | 5.25 | 8.26 | 8.70 | 12.33 | — |
Net Debt/EBITDA |
0.87 | 0.63 | 1.59 | 1.34 | 1.53 | 2.59 | 2.24 | 7.66 | — |
Debt/Assets |
0.00% | 0.17% | 0.15% | 0.16% | 0.11% | 0.05% | 0.12% | 0.02% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.03 | 0.04 | 0.10 | 0.07 | 0.02 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
3.41 | 0.62 | 0.90 | 0.83 | 0.90 | 0.68 | 0.89 | 0.43 | — |
Capex/Depreciation |
0.35 | 0.17 | (0.01) | (0.27) | (0.23) | (0.58) | (1.96) | (1.45) | — |
| (196.92%) | (415.84%) | (89.48%) | (66.55%) | (63.41%) | (139.92%) | 132.92% | 35.44% | — | |
| (30.50%) | (118.41%) | (58.80%) | (50.28%) | (51.26%) | (52.71%) | (41.11%) | (25.87%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(38.10%) | (306.81%) | (72.80%) | (91.27%) | (74.77%) | (47.66%) | (45.48%) | (15.88%) | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
3,177.17% | 1,781.22% | 470.35% | 611.76% | 2,389.38% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
947.76% | 578.71% | 197.15% | 189.90% | 654.44% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
230.74% | 214.25% | 81.47% | 105.65% | 308.72% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
0.52 | (0.15) | 0.90 | 2.26 | 0.33 | — | — | — | — |
Graham Number |
0.00 | 46.63 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Earnings Yield |
(14.59%) | (52.46%) | (223.90%) | (240.43%) | (26.96%) | — | — | — | — |
Free Cash Flow Yield |
(90.03%) | (32.40%) | (87.39%) | (200.16%) | (24.64%) | — | — | — | — |
Revenue per Share |
0.22 | 0.63 | 6.06 | 8.14 | 2.73 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(8.35) | (12.89) | (30.82) | (46.49) | (72.55) | (185.89) | (582.40) | (126.81) | — |
Capex per Share |
(0.04) | (0.02) | (0.01) | (0.55) | (0.56) | (5.17) | (34.69) | (52.75) | — |
Free Cash Flow per Share |
(8.39) | (12.91) | (30.83) | (47.04) | (73.11) | (191.06) | (617.10) | (179.56) | — |
Cash per Share |
7.89 | 9.11 | 52.97 | 73.75 | 119.75 | 610.95 | 1,471.99 | 1,915.39 | — |
Shareholders Equity per Share |
5.42 | (4.62) | 35.93 | 60.84 | 115.88 | 550.79 | (808.11) | (288.22) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
5.42 | (4.62) | 35.93 | 60.84 | 115.88 | 550.79 | (808.11) | (288.22) | — |
Free Cash Flow |
(82.94) | (80.87) | (79.02) | (80.33) | (116.55) | (76.33) | (49.55) | (8.56) | — |
Working Capital |
61.63 | 40.40 | 117.18 | 100.42 | 165.47 | 219.74 | 106.41 | 84.88 | — |
Capital Expenditures |
(0.44) | (0.13) | (0.02) | (0.94) | (0.89) | (2.06) | (2.79) | (2.52) | — |
Net Current Asset Value |
47.87 | (36.93) | 81.64 | 90.75 | 153.79 | 204.75 | (91.18) | (29.11) | — |
EV/EBIT |
0.00 | 0.00 | 0.51 | 0.88 | 0.00 | — | — | — | — |
Capex to Sales |
0.20 | 0.03 | 0.00 | 0.07 | 0.20 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
(0.67) | (0.32) | 0.81 | 0.73 | 0.63 | 0.44 | 0.17 | 0.60 | — |
Cash ROIC |
(63.07%) | (286.80%) | (34.64%) | (34.92%) | (31.01%) | (16.44%) | (92.64%) | (11.03%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Average Payables |
3.28 | 2.54 | 3.63 | 3.88 | 3.16 | 3.54 | 3.37 | 3.37 | — |
Average Assets |
79.31 | 110.81 | 149.11 | 191.03 | 250.34 | 205.91 | 127.13 | 53.87 | — |
Average Common Equity |
12.29 | 31.55 | 97.99 | 144.32 | 202.39 | 77.57 | (39.32) | (39.32) | — |
Columns are period end dates · fundamentals updated 6 Nov 2026